62
Participants
Start Date
March 22, 2021
Primary Completion Date
November 15, 2022
Study Completion Date
November 15, 2022
JZP-258
Maximum nightly dosage of 9 grams, administered once, twice or thrice nightly, with no single dose \> 6 g
Geisinger Clinic, Danville
The Center for Sleep & Wake Disorders, Chevy Chase
Clinical Research of Gastonia, Gastonia
Bogan Sleep Consultants, LLC, Columbia
Medical University of South Carolina, Department of Psychiatry and Behavioral Sciences, North Charleston
Clinical Research of Rock Hill, Rock Hill
Clinical Research Institute, Stockbridge
Sleep Practitioners LLC, Macon
Florida Pediatric Research Institute, LLC, Winter Park
Clinical Research of West Florida, Inc, Tampa
Pulmonary Disease Specialists, PA d/b/a PDS Research, Kissimmee
Wright Clinical Research, LLC, Alabaster
Sleep Disorders Center of Alabama, Birmingham
Pulmonary Associates of the Southeast, PC, Birmingham
Ohio Sleep Medicine Institute, Dublin
Cleveland Clinic, Sleep Disorders Center, Cleveland
Intrepid Research LLC, Cincinnati
WMed Center for Clinical Research, Kalamazoo
Minnesota Lung Center, Edina
Clayton Sleep Institute, LLC, St Louis
Sleep Therapy & Research Center, San Antonio
FutureSearch Trials of Neurology, Austin
Delta Waves, Inc., Colorado Springs
Santa Monica Clinical Trials, Los Angeles
Southern California Institute For Respiratory Diseases, Inc./ Tower Sleep Medicine, Los Angeles
Southern California Institute For Respiratory Diseases, Inc., Los Angeles
SDS Clinical Trials, Inc, Santa Ana
Stanford University- Sleep Medicine, Redwood City
Lead Sponsor
Jazz Pharmaceuticals
INDUSTRY